Protein kinases that phosphorylate splicing factors: Roles in cancer development, progression and possible therapeutic options.

[1]  H. Kędzierska,et al.  Splicing factors of SR and hnRNP families as regulators of apoptosis in cancer. , 2017, Cancer letters.

[2]  Juraj Dobiáš,et al.  Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - A possible way to dual VEGFR2 TK/CLK ligands. , 2017, European journal of medicinal chemistry.

[3]  F. Zhan,et al.  NEK2 Promotes Aerobic Glycolysis in Multiple Myeloma Through Regulating Splicing of Pyruvate Kinase , 2017, Journal of Hematology & Oncology.

[4]  M. Carmo-Fonseca,et al.  Transcription Dynamics Prevent RNA-Mediated Genomic Instability through SRPK2-Dependent DDX23 Phosphorylation. , 2017, Cell reports.

[5]  M. Lai,et al.  Long non-coding RNA LINC01133 inhibits epithelial-mesenchymal transition and metastasis in colorectal cancer by interacting with SRSF6. , 2016, Cancer letters.

[6]  Manyi Yang,et al.  Increased NEK2 in hepatocellular carcinoma promotes cancer progression and drug resistance by promoting PP1/Akt and Wnt activation. , 2016, Oncology reports.

[7]  Prabhjot S. Mundi,et al.  AKT in cancer: new molecular insights and advances in drug development , 2016, British journal of clinical pharmacology.

[8]  Chunhui Zhou,et al.  Serine‐arginine protein kinase 1 promotes a cancer stem cell‐like phenotype through activation of Wnt/β‐catenin signalling in NSCLC , 2016, The Journal of pathology.

[9]  G. Hoser,et al.  Decreased Expression of SRSF2 Splicing Factor Inhibits Apoptotic Pathways in Renal Cancer , 2016, International journal of molecular sciences.

[10]  P. Jordan,et al.  Targeting the serrated pathway of colorectal cancer with mutation in BRAF. , 2016, Biochimica et biophysica acta.

[11]  Xiang-Dong Fu,et al.  Release of SR Proteins from CLK1 by SRPK1: A Symbiotic Kinase System for Phosphorylation Control of Pre-mRNA Splicing. , 2016, Molecular cell.

[12]  Jian Wang,et al.  SRPK2 promotes the growth and migration of the colon cancer cells. , 2016, Gene.

[13]  Athina Mavrou,et al.  SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing , 2016, Pharmacological research.

[14]  Yang Wang,et al.  An extensive program of periodic alternative splicing linked to cell cycle progression , 2016, eLife.

[15]  Mingjun Wu,et al.  RETRACTED ARTICLE: The Critical Role of SRPK1 in EMT of Human Glioblastoma in the Spinal Cord , 2016, Molecular Neurobiology.

[16]  Peng Zhang,et al.  Effect of silencing NEK2 on biological behaviors of HepG2 in human hepatoma cells and MAPK signal pathway , 2016, Tumor Biology.

[17]  A. Kyritsis,et al.  Expression of SRPK1 in gliomas and its role in glioma cell lines viability , 2016, Tumor Biology.

[18]  R. Ketteler,et al.  Benzobisthiazoles Represent a Novel Scaffold for Kinase Inhibitors of CLK Family Members , 2015, Biochemistry.

[19]  Lei Lu,et al.  Clinical significance and prognostic value of Nek2 protein expression in colon cancer. , 2015, International journal of clinical and experimental pathology.

[20]  J. Oxley,et al.  Serine-arginine protein kinase 1 (SRPK1), a determinant of angiogenesis, is upregulated in prostate cancer and correlates with disease stage and invasion , 2015, Journal of Clinical Pathology.

[21]  J. Stenvang,et al.  Topoisomerase‐1 gene copy aberrations are frequent in patients with breast cancer , 2015, International journal of cancer.

[22]  H. Gautrey,et al.  SRSF3 and hnRNP H1 regulate a splicing hotspot of HER2 in breast cancer cells , 2015, RNA biology.

[23]  W. Zhong,et al.  Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer , 2015, BMC Urology.

[24]  M. D. Polêto,et al.  Potential Antileukemia Effect and Structural Analyses of SRPK Inhibition by N-(2-(Piperidin-1-yl)-5-(Trifluoromethyl)Phenyl)Isonicotinamide (SRPIN340) , 2015, PloS one.

[25]  Yang Xu,et al.  Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy , 2015, Biomolecules.

[26]  Yahong Sun,et al.  The crucial role of SRPK1 in TGF-β-induced proliferation and apoptosis in the esophageal squamous cell carcinomas , 2015, Medical Oncology.

[27]  G. Dellaire,et al.  Connecting the speckles: Splicing kinases and their role in tumorigenesis and treatment response , 2015, Nucleus.

[28]  M. Hagiwara,et al.  Identification of a Dual Inhibitor of SRPK1 and CK2 That Attenuates Pathological Angiogenesis of Macular Degeneration in Mice , 2015, Molecular Pharmacology.

[29]  J. Gribben,et al.  Empirical inference of circuitry and plasticity in a kinase signaling network , 2015, Proceedings of the National Academy of Sciences.

[30]  L. Poellinger,et al.  Increased Serine-Arginine (SR) Protein Phosphorylation Changes Pre-mRNA Splicing in Hypoxia* , 2015, The Journal of Biological Chemistry.

[31]  E. Levanon,et al.  Identification of recurrent regulated alternative splicing events across human solid tumors , 2015, Nucleic acids research.

[32]  Qianqian Wu,et al.  The influence of SRPK1 on glioma apoptosis, metastasis, and angiogenesis through the PI3K/Akt signaling pathway under normoxia , 2015, Tumor Biology.

[33]  Henry W. Long,et al.  CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer. , 2015, Cancer research.

[34]  Sylvia E. Le Dévédec,et al.  Tumor cell migration screen identifies SRPK1 as breast cancer metastasis determinant. , 2015, The Journal of clinical investigation.

[35]  Xiang-Dong Fu,et al.  Conserved proline-directed phosphorylation regulates SR protein conformation and splicing function. , 2015, The Biochemical journal.

[36]  C. Le Page,et al.  PRP4K is a HER2-regulated modifier of taxane sensitivity , 2015, Cell cycle.

[37]  K. Tomczak,et al.  The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge , 2015, Contemporary oncology.

[38]  T. Nomura,et al.  Inhibitors of CLK Protein Kinases Suppress Cell Growth and Induce Apoptosis by Modulating Pre-mRNA Splicing , 2015, PloS one.

[39]  Z. Siegfried,et al.  The role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progression , 2015, Molecular & cellular oncology.

[40]  J. Davie,et al.  Alternative Splicing of MEF2C pre-mRNA Controls Its Activity in Normal Myogenesis and Promotes Tumorigenicity in Rhabdomyosarcoma Cells* , 2014, Journal of Biological Chemistry.

[41]  Jung-Chun Lin,et al.  Elevated SRPK1 lessens apoptosis in breast cancer cells through RBM4-regulated splicing events , 2014, RNA.

[42]  J. Oxley,et al.  SERINE ARGININE PROTEIN KINASE-1 (SRPK1) INHIBITION AS A POTENTIAL NOVEL TARGETED THERAPEUTIC STRATEGY IN PROSTATE CANCER , 2014, Oncogene.

[43]  F. Zhan,et al.  NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma , 2014, Oncotarget.

[44]  Hae-Yun Jung,et al.  Molecular Pathways: Linking Tumor Microenvironment to Epithelial–Mesenchymal Transition in Metastasis , 2014, Clinical Cancer Research.

[45]  Wenke Liu,et al.  Aberrant expression of NEK2 and its clinical significance in non-small cell lung cancer , 2014, Oncology letters.

[46]  R. Hartmann,et al.  Hydroxybenzothiophene Ketones Are Efficient Pre-mRNA Splicing Modulators Due to Dual Inhibition of Dyrk1A and Clk1/4. , 2014, ACS medicinal chemistry letters.

[47]  D. Bates,et al.  Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma , 2014, British Journal of Cancer.

[48]  D. Lane,et al.  Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response , 2014, Cell Death and Differentiation.

[49]  A. Newton,et al.  Both decreased and increased SRPK1 levels promote cancer by interfering with PHLPP-mediated dephosphorylation of Akt. , 2014, Molecular cell.

[50]  Zhong-yu Wang,et al.  Abnormal expression of Nek2 in pancreatic ductal adenocarcinoma: a novel marker for prognosis. , 2014, International journal of clinical and experimental pathology.

[51]  Haiyong Han,et al.  Therapeutic melting pot of never in mitosis gene a related kinase 2 (Nek2): a perspective on Nek2 as an oncology target and recent advancements in Nek2 small molecule inhibition. , 2014, Journal of medicinal chemistry.

[52]  Yi Lu,et al.  Upregulation of NEK2 is associated with drug resistance in ovarian cancer. , 2014, Oncology reports.

[53]  P. Chieffi,et al.  The centrosomal kinase NEK2 is a novel splicing factor kinase involved in cell survival , 2013, Nucleic acids research.

[54]  M. Moyer,et al.  Phosphorylation of SRSF1 by SRPK1 regulates alternative splicing of tumor-related Rac1b in colorectal cells , 2013, RNA.

[55]  Qianqian Wu,et al.  SRPK1 Dissimilarly Impacts on the Growth, Metastasis, Chemosensitivity and Angiogenesis of Glioma in Normoxic and Hypoxic Conditions , 2013, Journal of Cancer.

[56]  Levi C. T. Pierce,et al.  DNA Topoisomerases Participate in Fragility of the Oncogene RET , 2013, PloS one.

[57]  S. Knapp,et al.  Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD. , 2013, Investigative ophthalmology & visual science.

[58]  Q. Gao,et al.  Evaluation of Cancer Dependence and Druggability of PRP4 Kinase Using Cellular, Biochemical, and Structural Approaches , 2013, The Journal of Biological Chemistry.

[59]  C. Sette,et al.  Phosphorylation-Mediated Regulation of Alternative Splicing in Cancer , 2013, International journal of cell biology.

[60]  Min Liu,et al.  miR-371-5p down-regulates pre mRNA processing factor 4 homolog B (PRPF4B) and facilitates the G1/S transition in human hepatocellular carcinoma cells. , 2013, Cancer letters.

[61]  A. Pries,et al.  Regulation of pro-angiogenic tissue factor expression in hypoxia-induced human lung cancer cells. , 2013, Oncology reports.

[62]  Thomas C. Coombs,et al.  Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. , 2013, Bioorganic & medicinal chemistry letters.

[63]  T. Huh,et al.  Curcumin induces apoptosis in human colorectal carcinoma (HCT-15) cells by regulating expression of Prp4 and p53 , 2013, Molecules and cells.

[64]  Qing Deng,et al.  SRPK1 contributes to malignancy of hepatocellular carcinoma through a possible mechanism involving PI3K/Akt , 2013, Molecular and Cellular Biochemistry.

[65]  O. Mühlemann,et al.  Paraquat Modulates Alternative Pre-mRNA Splicing by Modifying the Intracellular Distribution of SRPK2 , 2013, PloS one.

[66]  L. Meijer,et al.  Chemical synthesis and biological validation of immobilized protein kinase inhibitory Leucettines. , 2013, European journal of medicinal chemistry.

[67]  Xiang-Dong Fu,et al.  Regulation of splicing by SR proteins and SR protein-specific kinases , 2013, Chromosoma.

[68]  E. Brambilla,et al.  A new function of the splicing factor SRSF2 in the control of E2F1-mediated cell cycle progression in neuroendocrine lung tumors , 2013, Cell cycle.

[69]  Ngoc Thang Vu,et al.  hnRNP U Enhances Caspase-9 Splicing and Is Modulated by AKT-dependent Phosphorylation of hnRNP L* , 2013, The Journal of Biological Chemistry.

[70]  A. Krainer,et al.  S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1. , 2013, Cell reports.

[71]  F. Zhan,et al.  NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. , 2013, Cancer cell.

[72]  E. Brambilla,et al.  Abnormal Expression of the Pre-mRNA Splicing Regulators SRSF1, SRSF2, SRPK1 and SRPK2 in Non Small Cell Lung Carcinoma , 2012, PloS one.

[73]  R. Bayliss,et al.  Cell cycle regulation by the NEK family of protein kinases , 2012, Journal of Cell Science.

[74]  Ryan M. Plocinik,et al.  The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus. , 2012, Molecular cell.

[75]  W. Ruf,et al.  Tissue factor proangiogenic signaling in cancer progression. , 2012, Thrombosis research.

[76]  M. Ladomery,et al.  WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. , 2011, Cancer cell.

[77]  M. Olivier,et al.  Biological functions of p53 isoforms through evolution: lessons from animal and cellular models , 2011, Cell Death and Differentiation.

[78]  J. Taunton,et al.  Irreversible Nek2 kinase inhibitors with cellular activity. , 2011, Journal of medicinal chemistry.

[79]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[80]  M. Shimada,et al.  Gene expression profile can predict pathological response to preoperative chemoradiotherapy in rectal cancer. , 2011, Cancer genomics & proteomics.

[81]  Rutger O. Vogel,et al.  Clk2 and B56β mediate insulin-regulated assembly of the PP2A phosphatase holoenzyme complex on Akt. , 2011, Molecules and Cells.

[82]  E. Brambilla,et al.  Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin , 2011, The EMBO journal.

[83]  J. Adams,et al.  Phosphorylation mechanism and structure of serine‐arginine protein kinases , 2011, The FEBS journal.

[84]  Damian Szklarczyk,et al.  Specific CLK Inhibitors from a Novel Chemotype for Regulation of Alternative Splicing , 2011, Chemistry & biology.

[85]  Amy J. Hawkins,et al.  Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a. , 2010, Cancer research.

[86]  J. Minna,et al.  hnRNP L regulates the tumorigenic capacity of lung cancer xenografts in mice via caspase-9 pre-mRNA processing. , 2010, The Journal of clinical investigation.

[87]  Michael C. Ryan,et al.  Genome-wide analysis of novel splice variants induced by topoisomerase I poisoning shows preferential occurrence in genes encoding splicing factors. , 2010, Cancer research.

[88]  E. Brambilla,et al.  The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo , 2010, Oncogene.

[89]  Felicie F. Andersen,et al.  Topoisomerase I deficiency results in chromosomal alterations in cervical cancer cells. , 2010, Anticancer research.

[90]  Cha Soon Kim,et al.  Phosphorylation of CLK2 at Serine 34 and Threonine 127 by AKT Controls Cell Survival after Ionizing Radiation* , 2010, The Journal of Biological Chemistry.

[91]  Yu Shyr,et al.  RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells , 2010, Breast Cancer Research.

[92]  A. Krainer,et al.  A rational nomenclature for serine/arginine-rich protein splicing factors (SR proteins). , 2010, Genes & development.

[93]  Lawrence B. Gardner,et al.  Nonsense-Mediated RNA Decay Regulation by Cellular Stress: Implications for Tumorigenesis , 2010, Molecular Cancer Research.

[94]  H. Urlaub,et al.  Human PRP4 kinase is required for stable tri-snRNP association during spliceosomal B complex formation , 2010, Nature Structural &Molecular Biology.

[95]  M. Ladomery,et al.  Regulation of Vascular Endothelial Growth Factor (VEGF) Splicing from Pro-angiogenic to Anti-angiogenic Isoforms , 2009, The Journal of Biological Chemistry.

[96]  J. D. Vos,et al.  Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription , 2009, Nature Cell Biology.

[97]  A. Levey,et al.  Interaction of Akt-phosphorylated SRPK2 with 14-3-3 Mediates Cell Cycle and Cell Death in Neurons* , 2009, The Journal of Biological Chemistry.

[98]  M. Hagiwara,et al.  Akt2 regulation of Cdc2-like kinases (Clk/Sty), serine/arginine-rich (SR) protein phosphorylation, and insulin-induced alternative splicing of PKCbetaII messenger ribonucleic acid. , 2009, Endocrinology.

[99]  Xiang-Dong Fu,et al.  Regulation of SR protein phosphorylation and alternative splicing by modulating kinetic interactions of SRPK1 with molecular chaperones. , 2009, Genes & development.

[100]  R. Franco,et al.  Increased expression and nuclear localization of the centrosomal kinase Nek2 in human testicular seminomas , 2009, The Journal of pathology.

[101]  A. Lazaris,et al.  Topoisomerase I and IIα protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy , 2008, Cancer Chemotherapy and Pharmacology.

[102]  M. Ladomery,et al.  Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors , 2008, Journal of Cell Science.

[103]  H. Mankin,et al.  Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer , 2008, Molecular Cancer Therapeutics.

[104]  S. Yang,et al.  Serine/arginine protein-specific kinase 2 promotes leukemia cell proliferation by phosphorylating acinus and regulating cyclin A1. , 2008, Cancer research.

[105]  S. Friedman,et al.  Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. , 2008, Gastroenterology.

[106]  S. Harper,et al.  VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy , 2008, British Journal of Cancer.

[107]  P. Dorrestein,et al.  A sliding docking interaction is essential for sequential and processive phosphorylation of an SR protein by SRPK1. , 2008, Molecular cell.

[108]  A. Mohan,et al.  SRPK1: A cisplatin sensitive protein expressed in retinoblastoma , 2008, Pediatric blood & cancer.

[109]  Ji Luo,et al.  Cancer Proliferation Gene Discovery Through Functional Genomics , 2008, Science.

[110]  C. Prigent,et al.  PRP4 is a spindle assembly checkpoint protein required for MPS1, MAD1, and MAD2 localization to the kinetochores , 2007, The Journal of cell biology.

[111]  A. Fry,et al.  Mitotic regulation by NIMA-related kinases , 2007, Cell Division.

[112]  A. Krainer,et al.  The gene encoding the splicing factor SF2/ASF is a proto-oncogene , 2007, Nature Structural &Molecular Biology.

[113]  L. Miller,et al.  Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. , 2007, Cancer research.

[114]  Juan Iovanna,et al.  Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[115]  M. Hagiwara,et al.  Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[116]  Liming Yang,et al.  A loss-of-function RNA interference screen for molecular targets in cancer , 2006, Nature.

[117]  Laurence J Miller,et al.  Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma. , 2006, Cancer research.

[118]  Leandro Quadrana,et al.  Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKT , 2005, Nature Structural &Molecular Biology.

[119]  Xiang-Dong Fu,et al.  Interplay between SRPK and Clk/Sty kinases in phosphorylation of the splicing factor ASF/SF2 is regulated by a docking motif in ASF/SF2. , 2005, Molecular cell.

[120]  Thomas M. Harris,et al.  Centronuclear myopathy in mice lacking a novel muscle-specific protein kinase transcriptionally regulated by MEF2. , 2005, Genes & development.

[121]  Yong-jie Lu,et al.  A combination of molecular cytogenetic analyses reveals complex genetic alterations in conventional renal cell carcinoma. , 2005, Cancer genetics and cytogenetics.

[122]  Andrew M Fry,et al.  The Centrosomal Kinase Nek2 Displays Elevated Levels of Protein Expression in Human Breast Cancer , 2004, Cancer Research.

[123]  E. Wiemer,et al.  Resistance to platinum-containing chemotherapy in testicular germ cell tumors is associated with downregulation of the protein kinase SRPK1. , 2004, Neoplasia.

[124]  Hiroshi Kimura,et al.  Manipulation of Alternative Splicing by a Newly Developed Inhibitor of Clks* , 2004, Journal of Biological Chemistry.

[125]  Y. Pommier,et al.  Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1 , 2004, Cancer Research.

[126]  J. Diehl,et al.  An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. , 2003, Cancer research.

[127]  N. Maihle,et al.  Characterization and Expression of Novel 60‐kDa and 110‐kDa EGFR Isoforms in Human Placenta , 2003, Annals of the New York Academy of Sciences.

[128]  D. Gillatt,et al.  VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. , 2002, Cancer research.

[129]  W. Bickmore,et al.  Mammalian PRP4 Kinase Copurifies and Interacts with Components of Both the U5 snRNP and the N-CoR Deacetylase Complexes , 2002, Molecular and Cellular Biology.

[130]  C. Bailly,et al.  Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506. , 2001, Cancer research.

[131]  M. Lai,et al.  Transportin-SR2 mediates nuclear import of phosphorylated SR proteins , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[132]  J. Holden,et al.  Expression of DNA topoisomerase I in neoplasms of the kidney: correlation with histological grade, proliferation, and patient survival. , 2000, Human pathology.

[133]  T. Pawson,et al.  The Protein Kinase Clk/Sty Directly Modulates SR Protein Activity: Both Hyper- and Hypophosphorylation Inhibit Splicing , 1999, Molecular and Cellular Biology.

[134]  J. Holden,et al.  Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression. , 1999, Human pathology.

[135]  M. Hagiwara,et al.  Novel SR-protein-specific kinase, SRPK2, disassembles nuclear speckles. , 1998, Biochemical and biophysical research communications.

[136]  J. Holden,et al.  Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas. , 1997, Molecular pathology : MP.

[137]  A. Klingenhoff,et al.  Functional analysis of the fission yeast Prp4 protein kinase involved in pre-mRNA splicing and isolation of a putative mammalian homologue. , 1997, Nucleic acids research.

[138]  T. Pawson,et al.  SRPK1 and Clk/Sty Protein Kinases Show Distinct Substrate Specificities for Serine/Arginine-rich Splicing Factors* , 1996, The Journal of Biological Chemistry.

[139]  J. Tazi,et al.  Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I , 1996, Nature.

[140]  T Pawson,et al.  The Clk/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution. , 1996, The EMBO journal.

[141]  S. Alahari,et al.  prp4 from Schizosaccharomyces pombe, a mutant deficient in pre-mRNA splicing isolated using genes containing artificial introns , 1991, Molecular and General Genetics MGG.

[142]  G. Pagès,et al.  VEGF Splicing and the Role of VEGF Splice Variants: From Physiological-Pathological Conditions to Specific Pre-mRNA Splicing. , 2015, Methods in molecular biology.

[143]  Jonathan M. Howard,et al.  The RNAissance family: SR proteins as multifaceted regulators of gene expression , 2015, Wiley interdisciplinary reviews. RNA.

[144]  L. Cipak,et al.  Prp4 kinase is required for proper segregation of chromosomes during meiosis in Schizosaccharomyces pombe. , 2013, Acta biochimica Polonica.